ANNX insider buying and SEC filings, explained
Annexon, Inc. · CIK 1528115
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$12.2M
Insiders who bought
3
Sold (not marked 10b5-1)
$313K
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Sep 24, 2026 | Purchase (code P) | Douglas Love (CEO and Director) bought 26,065 shares at about $3.83 ($100K), reported as a purchase (code P). Holdings up 7% to 390,476 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 25, 2026 |
| May 28, 2026 | Purchase (code P) | Muneer A Satter (Director) bought 613,497 shares indirectly at $5.41 ($3.3M), reported as a purchase (code P). Indirect holdings up 6% to 10,342,134 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 29, 2026 |
| May 11, 2026 | Purchase (code P) | William H. Carson (Director) bought 8,000 shares at $5.78 ($46K), reported as a purchase (code P). Holdings up 11% to 78,405 shares. | SEC filing Filed May 13, 2026 |
| Apr 10, 2026 | Purchase (code P) | William H. Carson (Director) bought 8,000 shares at $6.20 ($50K), reported as a purchase (code P). Holdings up 13% to 70,405 shares. | SEC filing Filed Apr 14, 2026 |
| Mar 10, 2026 | Purchase (code P) | William H. Carson (Director) bought 8,000 shares at $5.67 ($45K), reported as a purchase (code P). Holdings up 15% to 62,405 shares. | SEC filing Filed Mar 12, 2026 |
| Mar 2, 2026 | Sale | Dean Richard Artis (EVP & Chief Scientific Officer) sold 5,894 shares at about $5.43 ($32K). Holdings down 3% to 180,093 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 4, 2026 |
| Mar 2, 2026 | Sale | Ted Yednock (EVP & Chief Innovation Officer) sold 5,566 shares at about $5.42 ($30K). Holdings down 3% to 154,161 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 4, 2026 |
| Mar 2, 2026 | Sale | Michael Overdorf (EVP & Chief Business Officer) sold 4,339 shares at about $5.42 ($24K). Holdings down 2% to 182,625 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 4, 2026 |
| Mar 2, 2026 | Sale | Jamie Dananberg (Chief Medical Officer) sold 5,820 shares at about $5.43 ($32K). Holdings down 4% to 123,582 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 4, 2026 |
| Mar 2, 2026 | Sale | Jennifer Lew (CFO) sold 5,565 shares at about $5.42 ($30K). Holdings down 3% to 170,700 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 4, 2026 |
| Feb 18, 2026 | Sale | Dean Richard Artis (EVP & Chief Scientific Officer) sold 5,290 shares at about $5.10 ($27K). Holdings down 4% to 123,487 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 20, 2026 |
| Feb 18, 2026 | Sale | Ted Yednock (EVP & Chief Innovation Officer) sold 7,857 shares at about $5.11 ($40K). Holdings down 7% to 97,227 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 20, 2026 |
| Feb 18, 2026 | Sale | Michael Overdorf (EVP & Chief Business Officer) sold 6,225 shares at about $5.10 ($32K). Holdings down 5% to 124,464 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 20, 2026 |
| Feb 18, 2026 | Sale | Jamie Dananberg (Chief Medical Officer) sold 5,290 shares at about $5.10 ($27K). Holdings down 7% to 73,152 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 20, 2026 |
| Feb 18, 2026 | Sale | Jennifer Lew (CFO) sold 7,851 shares at about $5.11 ($40K). Holdings down 6% to 113,765 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 20, 2026 |
| Dec 30, 2025 | Purchase (code P) | William H. Carson (Director) bought 4,115 shares at $5.02 ($21K), reported as a purchase (code P). Holdings up 8% to 54,405 shares. | SEC filing Filed Jan 2, 2026 |
| Dec 1, 2025 | Purchase (code P) | William H. Carson (Director) bought 4,115 shares at about $4.47 ($18K), reported as a purchase (code P). Holdings up 9% to 50,290 shares. | SEC filing Filed Dec 3, 2025 |
| Dec 1, 2025 | Purchase (code P) | Jung Choi (Director) bought 33,000 shares indirectly (by trust) at about $4.19 ($138K), reported as a purchase (code P). New position of 33,000 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 3, 2025 |
| Nov 20–21, 2025 | Purchase (code P) | Muneer A Satter (Director) bought 822,613 shares indirectly between Nov 20, 2025 and Nov 21, 2025 at about $4.38 ($3.6M), reported as a purchase (code P). Indirect holdings up 9% to 9,728,637 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 21, 2025 |
| Nov 17–19, 2025 | Purchase (code P) | Muneer A Satter (Director) bought 1,500,000 shares indirectly between Nov 17, 2025 and Nov 19, 2025 at about $3.37 ($5.1M), reported as a purchase (code P). Indirect holdings up 20% to 8,906,024 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 19, 2025 |
14 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
2 insiders bought in 30 days
$8.8M in purchases since Nov 19, 2025 · Purchases traded Nov 19, 2025 to Dec 1, 2025 · Closed
| Insider | Value | Traded | Source |
|---|---|---|---|
| Muneer A Satter (Director) | $5.1M | Nov 19, 2025 | SEC filing |
| Muneer A Satter (Director) | $3.6M | Nov 21, 2025 | SEC filing |
| Jung Choi (Director) | $138K | Dec 1, 2025 | SEC filing |
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow ANNX in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.